RIVENPROST


Synonyms	(-)-ono-4819 ONO-4819 Rivenprost
Status
Molecule Category	UNKNOWN
UNII	1WBO45T413


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FBQUXLIJKPWCAO-AZIFJQEOSA-N
Smiles	COCc1cccc(C[C@H](O)/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCSCCCC(=O)OC)c1
InChI	InChI=1S/C24H34O6S/c1-29-16-18-6-3-5-17(13-18)14-19(25)8-9-20-21(23(27)15-22(20)26)10-12-31-11-4-7-24(28)30-2/h3,5-6,8-9,13,19-22,25-26H,4,7,10-12,14-16H2,1-2H3/b9-8+/t19-,20-,21-,22-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H34O6S
Molecular Weight	450.6
AlogP	2.94
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	13.0
Polar Surface Area	93.06
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	31.0

Bioactivity

Mechanism of Action	Action	Reference
Prostanoid EP4 receptor agonist	AGONIST	PubMed PubMed


Protein: Prostanoid EP4 receptor Description: Prostaglandin E2 receptor EP4 subtype Organism : Homo sapiens P35408 ENSG00000171522

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Lipid-like ligand receptor (family A GPCR) Prostanoid receptor	2	-	-	56	-

Assay Description	Organism	Bioactivity	Reference
Binding affinity to mouse EP3 receptor by competitive binding assay	Mus musculus	56.0 nM
Agonist activity at mouse EP4 receptor expressed in CHO cells assessed as cAMP production	Mus musculus	1.6 nM

Cross References

Resources	Reference
ChEBI	168543
ChEMBL	CHEMBL303960
DrugBank	DB16315
FDA SRS	1WBO45T413
Guide to Pharmacology	1930
PubChem	9803828
SureChEMBL	SCHEMBL2309978
ZINC	ZINC000003940680

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).